Skip to main content

Table 1 Baseline characteristics and demographics of patients included in the study

From: Comparison of two different folic acid doses with methotrexate – a randomized controlled trial (FOLVARI Study)

Mean ± SD (except where stated otherwise) Folic acid 10 mg per week (FA10) Folic acid 30 mg per week (FA30) P value
N = 51 N = 49
Age, years 44.8 ± 10.0 43.8 ± 11.9 0.7
Female, number (%) 44 (86) 41 (84) 0.8
Duration of disease, years 4.4 ± 4.1 5.2 ± 5.1 0.4
Disease activity score (DAS28(3)) 5.8 ± 0.9 5.7 ± 0.9 0.9
Tender joint count, 0–28 11.0 ± 4.8 11.2 ± 5.2 0.8
Swollen joint count, 0–28 5.1 ± 3.3 5.6 ± 3.6 0.5
HAQ, 0–3 1.1 ± 0.5 1.1 ± 0.5 0.7
Hemoglobin, g/dl 10.8 ± 1.7 10.9 ± 2.0 0.7
Serum albumin, g/dl 4.0 ± 0.5 3.9 ± 0.6 0.7
ESR, mm, first hour 65.4 ± 33.2 59.5 ± 30.0 0.3
Rheumatoid factor-positive, number (%) 42 (84) 35 (71) 0.2
ACPA-positive, number positive/number tested (%) 45/48 (94) 39/43 (91) 0.6
  1. DAS28(3) modified disease activity score using three variables, HAQ health assessment questionnaire (Indian), ACPA anti-citrullinated protein antibody